is an innovative, pre-programmed, non-invasive, handheld system that allows hospital patients with acute moderate to severe post-operative pain to self-dose with sufentanil sublingual tablets
to manage their pain.
Adverse events commonly observed with the sublingualadministration of buprenorphine/naloxone sublingual tablets
during clinical trials and post-marketing experience areheadache, nausea, vomiting, hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain andperipheral edema.
Ethypharm's sublingual tablet
achieves a rapid onset by incorporating an innovative, patented novel drug delivery technology which allows a rapid Fentanyl absorption and systemic exposure to the analgesic.
Stallergenes has been conducting a phase IIb/III clinical trial, with a sublingual tablet
in adults suffering from moderate to severe persistent allergic rhinitis to house dust mites, including 509 patients, over seven countries, with a full year of treatment from January to December 2008.
It is based on Orexo's unique and patented sublingual tablet
technology in which a rapidly dissolving tablet is placed under the tongue and the active substance is absorbed by the mucous membrane.
Orexo Pharmaceuticals has announced that a European Patent has been granted for one of their technology platforms, the sublingual tablet
All patients enrolled in this trial will be prescribed nitroglycerin, either in a sublingual tablet
form or a lingual spray, to relieve the pain associated with angina.
The company's late-stage pipeline includes ARX-04 (sufentanil sublingual tablet
, 30mcg) for the treatment of moderate-to-severe acute pain in a medically supervised setting; and Zalviso(TM) (sufentanil sublingual tablet
system) for the management of moderate-to-severe acute pain in adult patients in the hospital setting.
Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a regulatory update on Zalviso(TM) (sufentanil sublingual tablet
system) intended for the management of moderate-to-severe acute pain in adult patients in the hospital setting.
NASDAQ: DYGN; BSE: DYG) today announced that it has begun a multi-center pivotal Phase 3 trial with NicErase-SL, a non-nicotine sublingual tablet
to be used as an aid to smoking cessation.
Ford has worked with AcelRx as a consultant from 2013 to the present and has been instrumental in the development of a commercial strategy for Zalviso(TM) (sufentanil sublingual tablet
system), a drug-device combination product now approved in Europe for the management of acute moderate-to-severe post-operative pain in adult patients.
Zalviso is a system combining a drug and a device designed to deliver a sublingual tablet
formulation of sufentanil 15 mcg via a proprietary, pre-programmed, non-invasive, patient-controlled analgesia (PCA) device.